iBio Inc. [AMEX: IBIO] closed the trading session at $2.64 on 08/17/20. The day’s price range saw the stock hit a low of $2.40, while the highest price level was $2.67. The company report on August 10, 2020 that iBio Provides Update on IBIO-201 COVID-19 Vaccine Program.
– IBIO-201 Demonstrates Ability to Elicit anti-SARS-CoV-2 Immune Response in Preclinical Studies -.
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology corporation and biologics contract manufacturing organization, today provided an update on one of its proprietary vaccine candidates being designed to prevent infection from the SARS-CoV-2 virus. iBio is investigating an array of adjuvants in combination with iBio’s proprietary lichenase carrier molecule (“LicKMTM”) fused to a coronavirus subunit protein (“IBIO-201”) with the goal of producing a safe and effective vaccine for COVID-19 disease, and especially one for our most vulnerable populations, including the elderly.
The stocks have a year to date performance of 960.24 percent and weekly performance of -28.46 percent. The stock has been moved at 700.00 percent over the last six months. The stock has performed -32.48 percent around the most recent 30 days and changed 50.86 percent over the most recent 3-months.
If compared to the average trading volume of 28.33M shares, IBIO reached to a volume of 13969664 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about iBio Inc. [IBIO]:
Alliance Global Partners have made an estimate for iBio Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 26, 2020.
The Average True Range (ATR) for iBio Inc. is set at 0.71, with the Price to Sales ratio for IBIO stock in the period of the last 12 months amounting to 291.11. The Price to Book ratio for the last quarter was 52.80, with the Price to Cash per share for the same quarter was set at 0.07.
IBIO stock trade performance evaluation
iBio Inc. [IBIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -28.46. With this latest performance, IBIO shares dropped by -32.48% in over the last four-week period, additionally plugging by 700.00% over the last 6 months – not to mention a rise of 277.20% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBIO stock in for the last two-week period is set at 39.74, with the RSI for the last a single of trading hit 31.56, and the three-weeks RSI is set at 43.99 for iBio Inc. [IBIO]. The present Moving Average for the last 50 days of trading for this stock 2.96, while it was recorded at 2.62 for the last single week of trading, and 1.29 for the last 200 days.
iBio Inc. [IBIO]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and iBio Inc. [IBIO] shares currently have an operating margin of -773.49. iBio Inc.’s Net Margin is presently recorded at -871.80.
Return on Total Capital for IBIO is now -45.52, given the latest momentum, and Return on Invested Capital for the company is -51.60. Return on Equity for this stock declined to -188.88, with Return on Assets sitting at -47.76. When it comes to the capital structure of this company, iBio Inc. [IBIO] has a Total Debt to Total Equity ratio set at 1,010.31. Additionally, IBIO Total Debt to Total Capital is recorded at 90.99, with Total Debt to Total Assets ending up at 81.36. Long-Term Debt to Equity for the company is recorded at 1,001.66, with the Long-Term Debt to Total Capital now at 90.21.
Reflecting on the efficiency of the workforce at the company, iBio Inc. [IBIO] managed to generate an average of -$2,932,167 per employee. Receivables Turnover for the company is 23.47 with a Total Asset Turnover recorded at a value of 0.05.iBio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 1.70.
iBio Inc. [IBIO]: Insider Ownership positions
There are presently around $27 million, or 7.40% of IBIO stock, in the hands of institutional investors. The top three institutional holders of IBIO stocks are: BLACKROCK INC. with ownership of 4,328,238, which is approximately 425.788% of the company’s market cap and around 1.00% of the total institutional ownership; VANGUARD GROUP INC, holding 1,708,991 shares of the stock with an approximate value of $4.51 million in IBIO stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $1.85 million in IBIO stock with ownership of nearly 116.363% of the company’s market capitalization.
Positions in iBio Inc. stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 48 institutional holders increased their position in iBio Inc. [AMEX:IBIO] by around 7,580,515 shares. Additionally, 12 investors decreased positions by around 604,629 shares, while 9 investors held positions by with 1,978,857 shares. The mentioned changes placed institutional holdings at 10,164,001 shares, according to the latest SEC report filing. IBIO stock had 34 new institutional investments in for a total of 1,760,532 shares, while 9 institutional investors sold positions of 499,600 shares during the same period.